|

Numinus CEO Discussion: a LEADER in Psychedelic-Assisted Therapy? ( NUMI / LKYSF Stock)

Numinus Wellness (TSX.V: NUMI), (OTC: LKYSF), has been a constant topic of conversation on this channel. NUMI is a company working on psychedelic-assisted therapy: with MDMA for PTSD, in collaboration with MAPS; Ketamine Therapy for Depression; and Psilocybin therapy for addiction, That’s why we decided to invite NUMI’s CEO, Payton Nyquvest. I hope you all enjoy!

Timestamps
1:00 – What is Numinus’ mission?
2:37 – Numinus’ partnership with MAPS to treat PTSD with MDMA
9:54 – Numinus treating addiction with Psilocybin
13:35 – Using ketamine to treat Depression
18:45 – Growing natural Psilocybin vs Synthetic versions?
21:45 -The 5-year plan
26:38 – What will revenues look like?

Enjoy the episode!

Check out our website:
ThePsychedelicInvestor.com

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Numinus #NUMIStock
#numinus #numi #numistock

Similar Posts

  • MindMed Conference Call Recap & My THOUGHTS (MMED / MNMD)

    Hey guys! Here’s the recap of MindMed’s (MMED / MNMD/ MMQ) Q1 conference call. They added lots of color on their different projects, and provided us with a lot of interesting new information. So, in this episode, we will cover a few topics. These are:

    1. MindMed’s Mission
    2. Their Talent acquisition
    3. The Progress of their different clinical trials
    4. The future

    Timestamps:
    0:00 – Intro
    1:59 – MindMed’s Mission
    4:36 – MMED’s talent acquisition
    7:24 – MindMed’s clinical trial progress
    10:48 – Psychiatry department : Project Lucy
    14:17 – Addiction department : Project Layla (18MC)
    18:33 – Pain department: Project Angie to treat pain card
    22:56 – Neurology department: Project Flow using LSD microdosing to treat ADHD
    23:43 – MindMed (MMED / MNMD) and its future plans

    Enjoy!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @thepsychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    Video editing: @themyaholy
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #PsychedelicStocks #MNMD

  • Discussing Extraction and the Colorado Gray Market with Nick Gay

    In this episode, Dennis Walker sits down with Nick Gay, the Head of Product Development at Ousia Labs, to talk about what extraction is and why it has become a focus of many entrepreneurs in the psychedelic space, as well as discussing the massive gray market that is developing in Colorado.

  • MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies

    MindMed Releases Data on TWO Clinical Trials: A Closer Look Into MMED’s Psilocybin and LSD studies.

    Mind Medicine (MindMed), (NASDAQ: MNMD, NEO: MMED, DE: MMQ), announced that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany, conducted as part of MindMed’s ongoing collaboration with the UHB Liechti Lab.

    STUDIES:
    https://clinicaltrials.gov/ct2/show/NCT03912974?term=psilocybin+escitalopram&draw=2&rank=2

    https://clinicaltrials.gov/ct2/show/NCT03604744?term=LSD+PSilocybin&draw=2&rank=1

    https://mindmed.co/news/press-release/mindmed-and-liechti-lab-provide-results-from-their-psilocybin-rd-collaboration/?fbclid=IwAR2_2fUvNf-VTF36Sv6Oz-XB8PTjscqjMWMFF5CKBvKQU2yLMOI_ZP4aq18
    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #mindmed #mmed #mnmdstock

  • MindMed (MMED) Cluster Headaches LSD Trials Update (and response to criticisms)

    Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!

    P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”

    Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.

    Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.

    Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?

    🎵 Music: www.bensound.com

    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    #MindMed #mmed #mindmedstock #psychedelicstocks #mmedf